Anne Plested

Anne Plested

EU Regulation Change at ION Markets, Fidessa
Message Message me Posts: 35 Comments: 2
Bio I head up the regulation change programme in Europe. Since joining in 2009 I have played a significant role in the establishment of the Fidessa Regulation Team, monitoring and evaluating the regulatory environment and working on the impact analysis of Brexit, MiFID II and other major EU regulation. Career History More than 20 years' experience of the financial markets in London. Member of the Steering Committee for the FIX Trading Community's MMT (Market Model Typology) initiative. Regular contributor to FTC EMEA Regulatory Sub-Committee. May 2014 appointed by ESMA as an external stakeholder representative o



Catch 22: The share trading obligation

15 Aug 2019

MiFID II refined the definition of OTC trading for equities, making it more difficult for firms to trade away from recognised trading venues or outside of a systematic internaliser (SI). Introduced in 2018, the so-called share trading obligation (STO) effectively wrapped more regulation and transparency around EU share trading. As a consequence, t...


Time runs out on Swiss equivalence

02 Jul 2019

Over the weekend, the stock market equivalence granted to Switzerland by the European Commission expired. The limited-period equivalence, which was given in December 2017 and extended to 30 June 2019, has run out. Despite Swiss beliefs that all the conditions are still met for recognition by the EU, there was no letup in the EU’s resolve to see thi...


EU financial transaction tax proposal lives on

21 Jun 2019

Back in 2011, the European Commission proposed a common European financial transaction tax (FTT). Despite several postponements and a general lack of support across the EU, a co-operation of member states – including France, Germany, and Spain – remain determined to implement the tax. As per the progress report submitted last week to the European...


ESMA sheds light on OTC trade reporting under No-Deal

07 Mar 2019

ESMA has released a statement which amongst other things includes clarification for EU investment firms that they will have to publish their OTC trades via an EU APA if a UK counterparty is involved. Whilst in Europe this approach may serve to ensure post-trade transparency within the EU27, it is also true that the UK counterparty could be requir...